Immunovant’s plans for autoimmune asset; Wall Street worries about Moderna’s RSV candidate 

Plus, news about Novo Holdings, Gritstone Bio, Invivyd and Science 37:

Immunovant outlines big plans for its autoimmune program: The biotech now expects to launch four to five “potentially registrational” trials for IMVT-1402 by March 2025 and studies in up to 10 indications by March 2026. Immunovant touted the asset’s “best-in-class” potential after a Phase I study in healthy volunteers read out positively last November. — Max Gelman

Moderna’s stock takes a hit over RSV efficacy concerns: The biotech’s shares $MRNA on Friday closed 6.4% lower after analysts flagged follow-up data indicating the company’s experimental RSV vaccine, mRNA-1345, may potentially lose efficacy faster than GSK’s and Pfizer’s respective shots. “Specifically, 1345 saw a 25% decline after 8.6 months, while GSK saw a 7% decline after 14 months,” Cowen’s Tyler Van Buren…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks